the aid library

LIST OPTIONS

Filter

8267

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

External Link

Ebola: What Every Health Care Professional Should Know

University of Alabama at Birmingham (UAB) School of Nursing (2014)

The course has an emphasis on health care in the US: "health care professionals need to understand this virus as more patients in the United States are confirmed to have EVD and patients are being transported to the US for treatment". Does anyone know of similar online courses (in English and/or Fre... more

External Link

BMJ's Coronavirus (covid-19) Hub

British Medical Journal (2020) CC

BMJ has created a free resource on SARS-CoV-2 and covid-19 to inform diagnosis and treatment, and to promote the wellbeing and safety of staff and patients during this extremely stressful and challenging period. BMJ’s dedicated covid-19 hub not only draws on the latest peer reviewed research, n... more

External Link

Buruli ulcer: wound care and rehabilitation

Frimpong, M.; F. S.Sarfo, M. Sarpong Duah, et al. Dove Medical Press Limited (2016) C1

Buruli ulcer caused by Mycobacterium ulcerans is a neglected tropical disease characterized by extensive ulceration involving predominantly the upper and lower limbs of patients. The disease is common in rural tropical communities in West and Central Africa, where access to proper health care is lim... more

Download (377)

View PDF (204)

Community- Based Management of Acute Malnutrition (CMAM)

World Vision International (2017) C1

Community-Based Management of Acute Malnutrition (CMAM) is a decentralised community-based approach to treating acute malnutrition. Treatment is matched to the nutritional and clinical needs of the child, with the majority children receiving treatment at home using ready-to-use foods. In-patient car... more

Download (540)

View PDF (574)

GUIDELINES FOR GOOD CLINICAL LABORATORY PRACTICES (GCLP)

Indian Council of Medical Research (ICMR) (2008) C1

Guidelines for Good Clinical Laboratory Practices (GCLP) outlines the principles and procedures to be followed by medical laboratories involved in clinical research and/or patient care so as to provide quality data which can be used for health research and patient treatment. As the use of laboratory... more

Download (131)

View PDF (80)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (211)

View PDF (242)

The Core Elements of Outpatient Antibiotic Stewardship

Centers for Disease Control and Prevention CDC (2019) C_CDC

The Core Elements of Outpatient Antibiotic Stewardship provides a framework for antibiotic stewardship for outpatient clinicians and facilities that routinely provide antibiotic treatment. This report augments existing guidance for other clinical settings. In 2014 and 2015, respectively, CDC release... more

Download (708)

View PDF (443)

Guidelines for Pharmacovigilance and Medicine Information System in Rwanda

Ministry of Health, Rwanda (2011) C2

The purpose of these guidelines is to help health workers to participate in the process of continuous surveillance of safety and efficacy of the pharmaceutical products which are used in clinical practice, thus help to achieve the ultimate goal to make safer and more effective treatment available to... more

External Link

New Therapeutics for Chagas Disease: Charting a Course to Drug Approval

Man, A. & Segal, F. Intechopen (2022) CC

DOI: 10.5772/intechopen.102891Little progress has been made since the 1960s and 19. 70s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and opera... more

Download (240)

View PDF (277)

HIV and tuberculosis co-infection programmes

Avert Avert (2019) C2

People living with HIV who have a low CD4 count are at a much higher risk of falling ill from TB infection than HIV negative people. It is important to offer both HIV testing to TB patients and TB diagnosis in HIV patients. Early detection and effective treatment are essential to preventing TB... more

Download (61)

View PDF (99)

COPD Foundation Educational Materials - EPOC 201: Más allá de lo básico

COPD Foundation COPD Foundation (2022) CC2

The document provides comprehensive guidance for people with COPD, covering treatment and medication management, oxygen therapy, mucus control, exercise, smoking cessation, nutrition, associated conditions, and strategies to prevent exacerbations. It emphasizes patient education, self-management, an... more

Download (331)

View PDF (442)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (126)

View PDF (168)

occupied Palestinian territory COVID-19 Response Plan (27 March 2020)

UN Office for the Coordination of Humanitarian Affairs (OCHA) (2020) C_WHO

The primary focus of the plan continues to be prevention, preparedness and treatment of the the Novel Coronavirus (COVID-19) outbreak. Central to the plan are the following overall objectives: To prevent further transmission of COVID-19 in the oPt; To provide adequate care for patients aff... more

Download (1163)

View PDF (2811)

WHO Information Note on Revised Cholera Kit
recommended

World Health Organization (WHO) (2015) C_WHO

The WHO Cholera Kits 2020 provide essential medical and logistical supplies for responding to cholera outbreaks. Designed to support the first month of an outbreak, the kits include treatment supplies for 100 patients, laboratory testing materials, investigation tools, and infrastructure components ... more

External Link

Radiological and Nuclear Terrorism: Medical Response to Mass Casualties

Centers for Disease Control and Prevention (CDC) (2006) C_CDC

The purpose of this training is to prepare clinicians in first receiver settings to: (1) Identify factors impacting immediate medical response to mass casualties following major types of radiological incidents, and (2) Demonstrate appropriate patient assessment, triage, treatment and disposition dec... more

External Link

An overview of heart failure in low- and middle-income countries

Agbor, V.N.; Ntusi, N.A.B.; Noubiap, J.J. Cardiovascular Diagnosis and Therapy (2020) CC

Heart failure (HF) is a global public health concern with disproportionate socioeconomic, morbidity and mortality burden on low- and middle-income countries (LMICs). This review summarises contemporary data on the demographic and clinical characteristics, aetiologies, treatment, economic burden and ... more

Download (158)

View PDF (213)

Learn more about monkeypox as we record first confirmed case in SA

Saphra (2022) CC

South Africa has recorded its first case of monkeypox today, 23 June 2022. The Minister of Health Dr. Joe Phaahla explained that he received a report from the National Health Laboratory Services’ CEO that they have confirmed through laboratory tests the first case of monkeypox in South Africa. ... more

External Link

Resource Effective Strategies to Prevent and Treat Cardiovascular Disease

Schwalm, J.; McKee, M.; Huffman, M. et al. Circulation (2016) CC

Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the... more

Download (112)

View PDF (173)

Evaluation of the Affordable Medicines Programme in Ukraine

World Health Organization WHO, Regional Office of Europe (2019) C_WHO

This report reviews and analyses the Affordable Medicines Programme, which was introduced in Ukraine in April 2017 to provide patients with improved access to 23 outpatient medicines for the treatment of chronic noncommunicable diseases. The evaluation combines both quantitative and qualitative anal... more

WHO Information Note on Revised Cholera Kit recommended

WHO Information Note on Revised Cholera Kit
recommended